Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Rockwood NJ, Jeon M. Estimating complex measurement and growth models using the R package PLmixed. Multivar Behav Res. 2019 Mar;54(2):288-306. doi: 10.1080/00273171.2018.1516541
Walker AW, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease, 1980-2009. J Occup Med. 1983 May;25(5):409-25.